CytomX Therapeutics Inc (CTMX) Stock Price Down 2.6%
CytomX Therapeutics Inc (NASDAQ:CTMX) shares dropped 2.6% during trading on Wednesday . The company traded as low as $16.44 and last traded at $16.74, with a volume of 61,673 shares traded. The stock had previously closed at $17.19.
Separately, Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. CytomX Therapeutics presently has an average rating of “Buy” and a consensus target price of $19.00.
The firm’s market capitalization is $630.69 million. The stock has a 50-day moving average of $12.19 and a 200-day moving average of $11.62.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/cytomx-therapeutics-inc-ctmx-stock-price-down-2-6.html
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.02. CytomX Therapeutics had a negative return on equity of 91.59% and a negative net margin of 579.42%. Equities analysts expect that CytomX Therapeutics Inc will post ($1.59) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC boosted its stake in CytomX Therapeutics by 0.6% in the second quarter. Redmile Group LLC now owns 733,899 shares of the company’s stock worth $7,497,000 after buying an additional 4,200 shares in the last quarter. American International Group Inc. boosted its stake in CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock valued at $120,000 after buying an additional 7,333 shares during the period. Nationwide Fund Advisors boosted its stake in CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock valued at $132,000 after buying an additional 7,688 shares during the period. Geode Capital Management LLC boosted its stake in CytomX Therapeutics by 17.5% in the first quarter. Geode Capital Management LLC now owns 68,254 shares of the company’s stock valued at $880,000 after buying an additional 10,184 shares during the period. Finally, Rhumbline Advisers purchased a new stake in CytomX Therapeutics during the second quarter valued at approximately $152,000. 51.95% of the stock is owned by hedge funds and other institutional investors.
About CytomX Therapeutics
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Receive News & Ratings for CytomX Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CytomX Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.